{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:26:00Z","timestamp":1788830760510,"version":"build-2803163510"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsmedizin Rostock"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00415-024-12373-6","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T08:02:01Z","timestamp":1712736121000},"page":"4651-4654","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["An anti-PF4 antibody-related disorder with cerebral venous sinus thrombosis and thrombocytopenia initially presenting as intracranial hemorrhage"],"prefix":"10.1007","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9904-6436","authenticated-orcid":false,"given":"Matthias","family":"Wittstock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cantr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae-Yeon","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra V.","family":"J\u00fcrs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Wesche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Greger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Greinacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"12373_CR1","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","volume":"384","author":"A Greinacher","year":"2021","unstructured":"Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S (2021) Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 384:2092\u20132101. https:\/\/doi.org\/10.1056\/NEJMoa2104840","journal-title":"N Engl J Med"},{"issue":"11","key":"12373_CR2","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1001\/jamaneurol.2021.3619","volume":"78","author":"M S\u00e1nchezvanKammen","year":"2021","unstructured":"S\u00e1nchezvanKammen M, AguiardeSousa D, Poli S, Cordonnier C, Heldner MR, van de Munckhof A, Krzywicka K, van Haaps T, Ciccone A, Middeldorp S, Levi MM, Kremer Hovinga JA, Silvis S, Hiltunen S, Mansour M, Arauz A, Barboza MA, Field TS, Tsivgoulis G, Nagel S, Lindgren E, Tatlisumak T, Jood K, Putaala J, Ferro JM, Arnold M, Coutinho JM, Cerebral Venous Sinus Thrombosis With Thrombocytopenia Syndrome Study Group (2021) Characteristics and outcomes of patients with cerebral venous sinus thrombosis in SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. JAMA Neurol 78(11):1314\u20131323. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3619","journal-title":"JAMA Neurol"},{"key":"12373_CR3","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284127","author":"G Uzun","year":"2023","unstructured":"Uzun G, Zlamal J, Althaus K, Bevot A, Hennersdorf F, Wolska N, Jock A, Kern J, Icheva V, Poli S, Ernemann U, Neu A, Bakchoul T (2023) Cerebral venous sinus\u00a0thrombosis\u00a0and\u00a0thrombocytopenia\u00a0due to heparin-independent anti PF4\u00a0antibodies\u00a0after adenovirus infection. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2023.284127","journal-title":"Haematologica"},{"key":"12373_CR4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022136","author":"L Sch\u00f6nborn","year":"2023","unstructured":"Sch\u00f6nborn L, Esteban O, Wesche J et al (2023) Anti-PF4\u00a0immunothrombosis without proximate heparin or adenovirus vector vaccine exposure. Blood. https:\/\/doi.org\/10.1182\/blood.2023022136","journal-title":"Blood"},{"issue":"14","key":"12373_CR5","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1056\/NEJMc2309016","volume":"389","author":"E Lindhoff-Last","year":"2023","unstructured":"Lindhoff-Last E, Sch\u00f6nborn L, Zaninetti C, Warkentin TE, Greinacher A (2023) Rescue therapy in chronic prothrombotic autoimmune anti-PF4 disorder. N Engl J Med 389(14):1339\u20131341. https:\/\/doi.org\/10.1056\/NEJMc2309016","journal-title":"N Engl J Med"},{"issue":"12 Suppl 6","key":"12373_CR6","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1212\/wnl.59.12_suppl_6.s33","volume":"59","author":"TH Brannagan","year":"2002","unstructured":"Brannagan TH (2002) Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune neuropathie. Neurology 59(12 Suppl 6):S33-40. https:\/\/doi.org\/10.1212\/wnl.59.12_suppl_6.s33","journal-title":"Neurology"},{"issue":"17","key":"12373_CR7","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1056\/NEJM200104263441704","volume":"344","author":"TE Warkentin","year":"2001","unstructured":"Warkentin TE, Kelton JG (2001) Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344(17):1286\u20131292. https:\/\/doi.org\/10.1056\/NEJM200104263441704","journal-title":"N Engl J Med"},{"issue":"12","key":"12373_CR8","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood.2021014214","volume":"139","author":"L Sch\u00f6nborn","year":"2022","unstructured":"Sch\u00f6nborn L, Thiele T, Kaderali L, G\u00fcnther A, Hoffmann T, Seck SE, Selleng K, Greinacher A (2022) Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient. Blood 139(12):1903\u20131907. https:\/\/doi.org\/10.1182\/blood.2021014214","journal-title":"Blood"},{"issue":"891","key":"12373_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/pmj.76.891.12","volume":"76","author":"H Allroggen","year":"2000","unstructured":"Allroggen H, Abbott RJ (2000) Cerebral venous sinus thrombosis. Post Grad Med J 76(891):12\u201315. https:\/\/doi.org\/10.1136\/pmj.76.891.12","journal-title":"Post Grad Med J"},{"issue":"23","key":"12373_CR10","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","volume":"384","author":"M Scully","year":"2021","unstructured":"Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, Goldblatt D, Kotoucek P, Thomas W, Lester W (2021) Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med 384(23):2202\u20132211. https:\/\/doi.org\/10.1056\/NEJMoa2105385","journal-title":"N Engl J Med"},{"issue":"1","key":"12373_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/hematology.2023000503","volume":"2023","author":"A Greinacher","year":"2023","unstructured":"Greinacher A, Warkentin TE (2023) Thrombotic anti-PF4 immune disoreders: HIT, VITT, and beyond. Hematol Am Soc Hematol Educ Program 2023(1):1\u201310. https:\/\/doi.org\/10.1182\/hematology.2023000503","journal-title":"Hematol Am Soc Hematol Educ Program"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12373-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12373-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12373-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T10:28:58Z","timestamp":1720520938000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12373-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":11,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["12373"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12373-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,10]]},"assertion":[{"value":"21 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.W. reports personal fees from Astra Zeneca, which are outside the submitted work. D.C. has nothing to disclose. S.Y.W. has nothing to disclose. A.V.J. is supported by the Clinician Scientist Program of the Centre for Transdisciplinary Neurosciences Rostock (CTNR) of the University Medical Center Rostock, which is outside the submitted work. J. W. has nothing to disclose. N.G. has nothing to disclose. A. G. reports personal fees and\/or other from Instrumentation Laboratory, Macopharma, Portola, Biokit, Sanofi-Aventis, Blau Farmaceutics, Prosensa\/Biomarin, DRK-BSD NSTOB, DRK-BSD Baden-W\u00fcrtemberg\/Hessen, Roche, GTH e.V., Deutsche Forschungsgemeinschaft, Robert-Koch-Institut, Veralox, Dilaflor, Vakzine Projekt Management GmbH, GIZ Else-K\u00f6rner-Stiftung, AstraZeneca, Janssen Vaccines & Prevention B.V., Takeda Pharma, Falk Foundation e.V., European Medicines Agency, Mylan Germany, Biotest, all of which are outside the submitted work. T.T. reports personal fees and\/or other from Bristol Myers Squibb, Pfizer, Bayer, Chugai Pharma, Novo Nordisk, Novartis, Daichii Sankyo, and LFB Pharma, Leo Pharma, all of which are outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All the procedures performed were in accordance with the ethical standards of the institutional committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The patient gave her informed consent for this report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}